-
Daiichi Sankyo2024-10-02 16:32:02Final Real-World Results from MILOS German Cohort Demonstrate Strong Increase in LDL-C Goal Achievement With
-
Daiichi Sankyo2024-07-15 09:32:07Daiichi Sankyo Opens New Affiliate for Oncology in Greece
-
Daiichi Sankyo2024-08-06 16:38:16New subgroup analyses of CLEAR Outcomes data showed bempedoic acid reduced the risk of major adverse
-
Daiichi Sankyo2024-08-06 16:38:29Multidisciplinary Think Tank proposes recommendations to improve holistic cardiovascular care in Europe
-
Daiichi Sankyo2024-08-06 16:38:40First-in-class cholesterol-lowering treatment NILEMDO®▼ and its combination with ezetimibe, NUSTENDI®▼,
-
Daiichi Sankyo2024-03-25 09:37:57CHMP issues positive opinions for both bempedoic acid and the bempedoic acid / ezetimibe fixed-dose
-
Daiichi Sankyo2024-03-25 10:05:10Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small
-
Daiichi Sankyo2024-02-15 11:44:37Daiichi Sankyo investiert ca. eine Milliarde Euro in Deutschland: Standort Pfaffenhofen (Bayern) wird zu
-
Daiichi Sankyo2024-01-11 10:13:05Declaration of Principle Supply Chain Due Diligence Act
-
Daiichi Sankyo2024-01-03 13:44:14Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including